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S. aureus, H. influenzae, N. gonorrhoeae 
M. catarrhalis, V. cholerae, Enterobacteriaceae 








K.  pneumoniae, 2015: R to carbapenems 
P.  aeruginosa, 2015: R to carbapenems Acinetobacter spp., 2015: R to carbapenems 
E.  coli, 2015: R to carbapenems 
EU: 2012: 0.1% - 2015: 0.1% EU: 2012: 6.2% - 2015: 8.1% 
EU: 2012: 17.2% - 2015: 17.8% Italy: 2012: 83.1% - 2015: 78.3% 
How they become resistant to β-lactams? 
Exchange and spread among 
different bacterial species 




>2000 described  
(with very ≠ spectrum) 
Naturally present 










Identical by PFGE 
 
IMP: from ≤0.125 to 8 mg/L 
MEM: from ≤0.125 to 12 mg/L 
ERTA: from 0.094 to 8 mg/L 
Triple coronary 
bypass 
ERTA: 1 g/day 








































Grundmann et al., LID, Feb 2017 
70.6% 39.7% 
Nov, 2013 – Apr 2014 
455 hospitals 
36 countries 
44.6% 10.9% 36.5% 0.08% 
18.2% 26.0% 55.8% 
1. KPC:                 42.4% 
2. OXA-48-like:   38.1% 
3. NDM:               12.2% 
4. VIM:                 7.3% 
Good hydrolysis “No” hydrolysis 
ESBLs 
(Class A; e.g., CTX-Ms) 
AmpCs 
(Class C; e.g., CMYs) 
1.0* 
KPCs 
(Class A; e.g., KPC-2, KPC-3) 
7.6* Metallo-β-lactamases, MBLs 









*Catalytic efficiency for imipenem: kcat/Km [µM-1/s-1] 
KPC carbapenemases (class A) 
The Tn4401 transposon (10 Kb) is at the origin 
of acquisition and dissemination of blaKPC 
Tn4401 is carried by MDR plasmids (IncF, I2, 
X, A/C, R, ColE1) of which some hyperepidemic 
Tn4401/plasmids are carried by K.  pneumoniae 
hyperepidemic clones 
MLST gapA infB mdh pgi phoE rpoB tonB 
ST11 3 3 1 1 1 1 4 
ST37 2 9 2 1 13 1 16 
ST258 3 3 1 1 1 1 79 
ST277 3 1 1 1 1 1 43 
ST307 4 1 2 52 1 1 7 
ST327 2 1 1 1 10 1 19 
ST340 3 3 1 1 1 1 18 
ST376 2 6 1 3 8 1 27 
ST384 18 23 56 63 80 43 51 
ST388 16 24 59 27 29 22 105 
ST512 54 3 1 1 1 1 79 
IncFIIK2 
KPC-2 to KPC-22 
OXA-48-like carbapenemases (class D) 
First: 2001 
Composite transposon Tn1 999 Common hyperepidemic L plasmid (non-MDR) 
OXA-48 K. pneumoniae ESBL/OXA-48 K. pneumoniae OXA-48 variants: OXA-162, -163, -181, -204, -232, -244, -245 
Hyperepidemic clones 
E. coli ST131 
K. pneumoniae ST11, ST147 
NDM carbapenemases (class B, MBL) 
NDM-1 to NDM-17 
2008: male with UTI/colonized (back from India) 
2009: many UK patients who traveled in India/Pakistan 
Very promiscuous bla gene(s) 
2009-2012 (950 NDM strains) 
K. pneumoniae                    37.8% 
E. coli                                 28.2% 
Other Gram-neg. bacilli      12.0% 
Other Enterobacteriaceae 11.8% 
E. cloacae                            5.5% 
A. baumannii                        3.8% 
P. aeruginosa                        1.0% 
Not necessarily hyperepidemic clones! 
Many MDR plasmids 
Frequently co-carrying important 





Genetic structures Many species 









Standard culture approach 
Even 5-6 days  
to get the final report 
Septic shock  
Inappropriate antibiotics within the 
first 6 hours is associated with a  
5- fold higher mortality risk 
[Kumar A et al., Chest, 2009] 
CLSI 2017: M100-S27 
CLSI, Jan 2010 CLSI, 2017 EUCAST, 2017 
S R S R S [screening] R 
IMP ≤4 ≥16 ≤1 ≥4 ≤2  [>1] ≥16 
MEM ≤4 ≥16 ≤1 ≥4 ≤2  [>0.12] ≥16 
Fattouh R et al., AAC, March 2016 
1,022 Enterobacteriaceae (189 CPE) 
 
CLSI:  
- 14% had MICs in the S range 
- Screening tests (if used) captured 86% of the CPE 
 
EUCAST:  
- 20% had MICs in the S range 
- Screening tests captured 98% of the CPE  
Screening tests 
K.  pneumoniae 
KPC+ (control) 




CLSI: Modified Hodge test 
This test indicates the possible production of 
enzyme(s) able to hydrolyze carbapenems (i.e., 
meropenem) = generic CARBAPENEMASE 
ESBL or pAmpC producers 
with porin(s) loss 
Not good for NDMs 
CLSI: Modified Carbapenem Inactivation Method (mCIM) 
Pierce VM, JCM, Aug 2017 
1 µL loop bacteria 
2 mL TSB 
10µg MEM 







6-15 mm: Carbapenemase positive 
16-18 mm: Indeterminate results  
≥ 19 mm: No carbapenemases  
Single clinical laboratory 
Sens: 99%; Spec: 100% 
Nine laboratory study 
Sens: 97%; Spec: 99% 117 Enterobacteriaceae (94 CPE) 
Nordmann, EID, 2012 
CLSI: NP test 
<2 hrs 
Most CPE turned in 10-30 min 
 
!!!! OXA-48-like  
not always detected 
Need pre-extraction of enzymes (~30 min) 
Bromothymol blue 
A: NDM-1 E. coli 
B: OXA-23 A. baumannii 
C: OXA-48 K. pneumoniae 
D: E. coli ATCC 25922 
 Direct use of colonies! 
Inhibitor based approaches 
Combination disk test (CDT) Gradient diffusion strips 
Etest: Imipenem+EDTA / Imipenem 
KPC-producing K. pneumoniae 
VIM-producing K. pneumoniae 
NDM-producing K. pneumoniae 
Phenyl boronic acid Dipicolinic acid 
Rosco Diagnostica KPC/MBL confirmation kit 
50-85 Euro Bogaerts P, IJAA, 2016 
mcr mcr mcr 
~6 hrs ESBLs: TEM, SHV, CTX-M, BEL, PER, GES, VEB 
pAmpCs: CMY, DHA, FOX, ACC-1, ACT/MIR 
Carbapenemases: KPC, NDM, VIM, IMP, GIM, SPM, OXA-48, OXA-23, OXA-24, OXA-58 
Sensitivity and Specificity: both ~100% 
Amplex Eazyplex 
• Preparation (5 min) 
• No DNA extraction 
• Run time (<30 min) 
Version A Version B 
Genie II platform 
~55 Euro 
LAMP 
Loop-mediated isothermal Amplification 
Real-time fluorescent measurement 
94 carbapenemase-producing Enterobacteriaceae 
 
100% agreement with PCR/Sequencing of bla genes 




Generic activity in ~4.5 hrs 
Can be reduced ~30 min-2 hrs 
~20 min 19 carba producers (21 controls) 
Sens and Spec: 100% and 90% 
0.30 Euro* 
Preparation from +BCs: ~3 hrs 
Reaction in 5 min-1 h (max 2 hrs) 
Sens and Spec 98% and 100% 
Check-Direct Screening, Check-Points 
• Real-time multiplex PCR 
• Rapid preparation  








BD MAX Reagent strip 
~30 Euro 
Antonelli et al., DMID, 2016 
Limit of detection (LOD) 
Florence, Italy 
557 rectal swabs 
Summary of the results  
ChromID CARBA SMART (w/wo broth enrichment) 




TAT from 18-24 h (direct culture) or 48 h (broth enrichment)  
to 3 hrs 
18 (3%) unresolved 
Cepheid GeneXpert 
Real-time multiplex PCR 
- Smart fluidic system 
- Filtering and Sonication (DNA) 
- Fluorescent-labeled hybr. probes (6 colors)  






• Add aliquot to elution, vortex, transfer to port S 
• Insert cartridge to station (overall, 1 min) 
• Run time (<1 h) 
~50 Euro 
JCM, 54:7; 2016 
4 centers (2 USA, 1 UK, 1 Spain) 
July 2013 – Feb 2014 
633 samples 
Results (obtained in 32-48 min) Performance for different targets 
23.5% 
Sensitivity: 96.6% - Specificity: 98.6% 
50% of them spiked at 1.1 x 102 to 1.2 x 103 CFU/swab (LOD of Xpert) 
Verigene, Nanosphere 
• Load cartridge, consumables, and sample (5 min) 
• Automated sample preparation and processing 
• Place slide from cartridge in reader (2.5 hrs) 
Gram-negatives cartridge 
Microarray approach by 
using Au-nanoprobe as 
reporter and silver 
reduction to enhance signal 
~50 Euro 
Gilman K.H. Siu et al., Plos One, Oct 2015 
ID for Gram-negatives (agreement 90.5%) 
Multicenter study (4 hospitals) 
364 BCs (114 Gram-pos; 250 Gram-neg) 
Jan 2014 – May 2014 
40-99 h faster than routine 
K. variicola 80% 
Drug-Resistant Organisms 
• Preparation of the pouch  
• Add pouch to FilmArray station (overall, 2 min) 




(RT-PCR for RNA target) 
Multiplex real-time PCR  









8 centers in USA 
July 2012 - Feb 2014 
2,207 BC samples 

























Real-time long read whole genome sequencing 
(Point of care, POC) 
1-2 hrs enough reads/coverage  




Carbapenem-resistant strains have high prevalence and still increase 
- Most of them are carbapenemase producers 
- KPC, NDM, and OXA-48 are the most frequent enzymes 
- The genetic background and special clones support their spread 
Standard phenotypic tests do not detect all carbapenemase producers 
- The clinical breakpoints do not identify 15-20% of strains 
- Screening tests may improve detection (if implemented) 
- They are cheap, but time consuming (1-3 days) 
Non-molecular rapid tests 
- They are cheap and relatively fast, but provide only a generic detection  
Molecular rapid tests 
- Most identify only one or few carbapenemase genes 
- Most do not identify species and other important genes (ideal system!) 
- Only some are validated for clinical samples 
- They are expensive  
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